Tracking cancer cells during chemo
Treatments studied
Part of Cancer clinical trials.
This trial studies how proteins on circulating tumor cells change during chemotherapy in people with colorectal cancer that has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to get up and care for yourself (ECOG score 0-2)
- Your doctor says you are healthy enough for chemotherapy
- You do not have an active infection before starting the trial
- You have not had another cancer in the last 3 years (except some skin cancers)
- You do not have a second colorectal cancer that started at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
This trial studies how colorectal cancer that has spread becomes resistant to treatment. By taking biopsies over time, researchers hope to find new ways to target the cancer and help patients live longer.
This trial tests whether adding a targeted drug (anti-EGFR) to chemotherapy helps people with right-sided advanced colorectal cancer whose tumors have certain gene markers. It may offer a more personalized treatment option.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.
Hear when a new Objective Responsive Rate (ORR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.